Publications by authors named "K Tolba"
Purpose: This systematic review and meta-analysis of randomized controlled trials (RCTs) aimed to evaluate the efficacy and safety of septoplasty versus non-surgical management for patients experiencing nasal obstruction due to deviated nasal septum (DNS).
Methods: We conducted a comprehensive search of PubMed, Scopus, Embase, Web of Science, Cochrane Library, Clinicaltrials.gov, ICTRP, and ISRCTN for relevant RCTs.
Introduction: Squamous cell cancer (SqCC) is a lung cancer subtype with few targeted therapy options. Molecular characterization, that is, by next-generation sequencing (NGS), is needed to identify potential targets. Lung Cancer Master Protocol Southwest Oncology Group S1400 enrolled patients with previously treated stage IV or recurrent SqCC to assess NGS biomarkers for therapeutic sub-studies.
View Article and Find Full Text PDFPurpose: Timely biomarker testing remains out of reach for many patients with advanced non-small-cell lung cancer (aNSCLC). Here, we studied the quality-of-care implications of closing the gap in timely receipt of comprehensive genomic profiling (CGP) to inform first-line (1L) decisions.
Methods: Using a real-world clinicogenomic database, we studied testing and 1L treatment patterns in aNSCLC after the approval of pembrolizumab in combination with pemetrexed and carboplatin (May 10, 2017).
Background: Genomic fusions are potent oncogenic drivers across cancer types and many are targetable. We demonstrate the clinical performance of DNA-based comprehensive genomic profiling (CGP) for detecting targetable fusions.
Materials And Methods: We analyzed targetable fusion genes in >450 000 tissue specimens profiled using DNA CGP (FoundationOne CDx, FoundationOne).
Article Synopsis
- The study investigates the clinicopathologic and genomic characteristics of 891 patients with advanced solid tumors driven by RET fusions, utilizing both tissue-based and liquid-based next-generation sequencing (NGS) methods.
- RET fusions were notably identified in 523 patients with non-small cell lung cancer (NSCLC) and 368 with other solid tumors, with lung adenocarcinoma and thyroid papillary carcinoma showing the highest prevalence rates.
- The research revealed 61 novel RET fusions and confirmed that liquid biopsies are highly effective for detecting these fusions, particularly in patients with a composite tumor fraction of at least 1%.